The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. This year’s metric has recorded a Price decrease of -25.35%. However, over the past six months, we’ve seen a stronger performance of -40.89%. The price of ALLO leaped by -1.85% over the last 30 days. And in the last five days, it has surged by 11.19%.
Allogene Therapeutics Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $3.78 on 02/19/25, while the lowest price for the same duration was marked at $1.23 on 04/09/25.
52-week price history of ALLO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Allogene Therapeutics Inc’s current trading price is -57.94% away from its 52-week high, while its distance from the 52-week low is 29.27%. The stock’s price range during this period has varied between$1.23 and $3.78. The Allogene Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.32 million for the day, a figure considerably lower than their average daily volume of 5.37 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Allogene Therapeutics Inc (ALLO) has experienced a quarterly decline of -13.59% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 345.46M and boasts a workforce of 229 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.8863, with a change in price of -0.6200. Similarly, Allogene Therapeutics Inc recorded 4,417,396 in trading volume during the last 100 days, posting a change of -28.05%.
ALLO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ALLO stands at 0.21. Similarly, the long-term debt-to-equity ratio is also 0.20.
ALLO Stock Stochastic Average
As of today, Allogene Therapeutics Inc’s raw stochastic average for the last 50 days stands at 14.12%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 76.60%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 52.87% and 45.10%, respectively.
